Search Results 721-730 of 16640 for ������������KA���:ZA31���24������ ���������������������������������

  1. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  3. Barriers to Achieving Diabetes Excellence in an American Indian Community in Minnesota - Mayo Clinic

    Rochester, Minnesota: 24-001808. About this study. The purpose of this study is to conduct a survey and focus group of individuals with diabetes and key ...

  4. Hydralazine and hydrochlorothiazide (oral route) - Mayo Clinic

    This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure also may ...

  5. Transcatheter Aortic Valve Replacement for Transcatheter Aortic Valve Failure - Mayo Clinic

    Rochester, Minnesota: 24-013299. About this study. The purpose of this study is to generate clinical evidence on valve safety and performance in subjects ...

  6. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  8. Atrial tachycardia - Symptoms and causes - Mayo Clinic

    Accessed June 24, 2024. What is an arrhythmia? National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/arrhythmias. Accessed July 14 ...

  9. A Study to Evaluate KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

    The study will be double-blinded for the first 28 weeks followed by an open label extension period of 24 weeks. After un-blinding, the subjects on KD025 ...

  10. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...